# Literature Gap Analysis — Interpreted Report

**Generated:** 2026-08-28 08:43
**Source:** PubMed E-utilities API (esearch.fcgi)
**Date range:** 2020/01/01 to 2026/07/17
**Domains analyzed:** 30
**Pairs analyzed:** 435

---

## Methodology

This analysis queries PubMed for publication counts across 30 diabetes research domains, both individually and as pairwise combinations (435 pairs). The **Gap Score** measures how much less cross-domain work exists compared to what each domain's individual activity would predict.

**Formula:** `Gap Score = max(0, 1 - (joint_publications / geometric_mean(domain1_count, domain2_count))) × 100`

**Interpretation:** A Gap Score of 95 means the intersection has 95% fewer publications than the geometric mean of the two domains' individual counts. This is a *relative* measure of cross-domain activity, not an absolute judgment of research need.

**Important caveats:**
- PubMed search matching is approximate (keyword-based, not exact MeSH)
- Low co-publication may indicate: (a) genuinely unexplored territory, (b) terminology mismatch across fields, (c) research published under different keywords, or (d) fields that are *methodologically distinct* and would not naturally overlap
- This analysis should be cross-referenced with domain expert knowledge before drawing conclusions
- All gap classifications below are preliminary and labeled with confidence levels per the Research Doctrine

---

## Potentially Meaningful Research Gaps

These domain pairs have low co-publication rates **and** plausible scientific reasons why cross-domain work could yield new insights. These represent the highest-value opportunities for computational contribution.

**Validation level: BRONZE** (single analytical source; requires expert confirmation)

| Rank | Domain 1 | Domain 2 | Gap Score | Joint Pubs | Rationale |
|------|----------|----------|-----------|------------|-----------|
| 1 | Treg / CAR-T | Neuropathy | 100.0 | 0 | Immune-mediated neuropathy in diabetes could potentially benefit from Treg modulation, but no work bridges these fields. |
| 2 | Beta Cell Regen | Health Equity | 100.0 | 0 | Regenerative therapies must address who has access to them. Equity analysis of emerging cell therapies is absent. |
| 3 | Treg / CAR-T | Health Equity | 100.0 | 0 | Advanced immunotherapies risk widening health disparities. No equity analysis of CAR-Treg/TCR-Treg access exists. |
| 4 | Glucokinase | Health Equity | 100.0 | 0 | If glucokinase activators succeed, global access will be critical. No equity analysis exists for this drug class. |
| 5 | Gene Therapy | LADA | 100.0 | 0 | LADA's autoimmune mechanism makes it a candidate for gene therapy approaches, but no crossover work exists. |
| 6 | Drug Repurposing | Health Equity | 100.0 | 0 | Drug repurposing could yield more affordable treatments for underserved populations, but equity is absent from repurposing research. |
| 7 | Insulin Resistance | Islet Transplant | 91.9 | 1 | Insulin resistance in islet transplant recipients affects graft survival, but this interaction is barely studied. |

---

## Methodologically Distinct Pairs (Expected Low Overlap)

These domain pairs have low co-publication because they use fundamentally different research methods (e.g., genetic association studies vs. medical device engineering). Low overlap here does **not** indicate a missed opportunity — it reflects the natural structure of the research landscape.

| Domain 1 | Domain 2 | Gap Score | Joint Pubs | Note |
|----------|----------|-----------|------------|------|
| GWAS / Polygenic | Closed Loop / AP | 100.0 | 0 | These domains use fundamentally different methods (e.g., genomics vs. device eng |
| Drug Repurposing | CGM Technology | 100.0 | 0 | These domains use fundamentally different methods (e.g., genomics vs. device eng |
| Islet Transplant | GWAS / Polygenic | 100.0 | 0 | These domains use fundamentally different methods (e.g., genomics vs. device eng |
| Personalized Nutr | Closed Loop / AP | 100.0 | 0 | These domains use fundamentally different methods (e.g., genomics vs. device eng |
| GWAS / Polygenic | CGM Technology | 96.7 | 3 | These domains use fundamentally different methods (e.g., genomics vs. device eng |
| Treg / CAR-T | CGM Technology | 93.8 | 1 | These domains use fundamentally different methods (e.g., genomics vs. device eng |

---

## Unclassified Gaps (Require Expert Review)

These domain pairs show high gap scores but have not been classified as either meaningful or methodologically distinct. Domain expert input is needed.

| Domain 1 | Domain 2 | Gap Score | Joint Pubs |
|----------|----------|-----------|------------|
| Insulin Resistance | Closed Loop / AP | 96.9 | 3 |
| Neuropathy | Gestational DM | 96.7 | 4 |
| Nephropathy DKD | Gestational DM | 95.5 | 24 |
| SGLT2 Inhibitors | Gestational DM | 94.7 | 15 |
| Insulin Resistance | Health Equity | 93.0 | 7 |
| Retinopathy | Gestational DM | 92.5 | 48 |
| Beta Cell Regen | Retinopathy | 91.9 | 5 |
| SGLT2 Inhibitors | Personalized Nutr | 91.8 | 1 |
| Drug Repurposing | Gestational DM | 91.4 | 2 |
| Epigenetics | LADA | 90.9 | 1 |
| Insulin Resistance | Retinopathy | 90.3 | 82 |
| Insulin Resistance | CGM Technology | 90.2 | 33 |
| Islet Transplant | Gestational DM | 89.4 | 1 |
| Gene Therapy | Gestational DM | 87.4 | 11 |
| Metabolomics | Health Equity | 87.1 | 8 |
| Proteomics | Closed Loop / AP | 86.9 | 3 |
| Autoimmunity T1D | Health Equity | 86.8 | 3 |
| GLP-1 Agonists | Gestational DM | 86.6 | 67 |
| Nephropathy DKD | Closed Loop / AP | 86.6 | 9 |
| Glucokinase | Neuropathy | 85.2 | 1 |
| Beta Cell Regen | CV Complications | 85.1 | 14 |
| Retinopathy | Closed Loop / AP | 85.0 | 12 |
| Autoimmunity T1D | SGLT2 Inhibitors | 84.7 | 13 |
| Microbiome Gut | Health Equity | 84.5 | 8 |
| Islet Transplant | Microbiome Gut | 84.4 | 1 |
| Epigenetics | Health Equity | 84.0 | 6 |
| Autoimmunity T1D | Gestational DM | 83.3 | 29 |
| Epigenetics | Closed Loop / AP | 83.3 | 6 |
| Glucokinase | Retinopathy | 83.3 | 6 |
| Metabolomics | Closed Loop / AP | 83.2 | 10 |
| Proteomics | CGM Technology | 82.7 | 14 |
| Autoimmunity T1D | Retinopathy | 82.3 | 34 |
| AI / ML Predict | LADA | 82.0 | 3 |
| Microbiome Gut | Closed Loop / AP | 81.7 | 9 |
| Neuropathy | Health Equity | 80.9 | 3 |
| Islet Transplant | Retinopathy | 80.8 | 2 |
| Personalized Nutr | Neuropathy | 80.8 | 1 |

---

## Individual Domain Publication Volumes (2020+)

| Domain | Publications | Relative Activity |
|--------|-------------|-------------------|
| Prevention / DPP | 80,135 | ████████████████████ |
| CV Complications | 25,757 | ██████░░░░░░░░░░░░░░ |
| Insulin Resistance | 20,020 | ████░░░░░░░░░░░░░░░░ |
| Retinopathy | 16,837 | ████░░░░░░░░░░░░░░░░ |
| Gestational DM | 15,223 | ███░░░░░░░░░░░░░░░░░ |
| Nephropathy DKD | 14,061 | ███░░░░░░░░░░░░░░░░░ |
| GLP-1 Agonists | 13,136 | ███░░░░░░░░░░░░░░░░░ |
| Metabolomics | 12,499 | ███░░░░░░░░░░░░░░░░░ |
| AI / ML Predict | 11,450 | ██░░░░░░░░░░░░░░░░░░ |
| Microbiome Gut | 10,346 | ██░░░░░░░░░░░░░░░░░░ |
| Youth Diabetes | 8,022 | ██░░░░░░░░░░░░░░░░░░ |
| Epigenetics | 7,554 | █░░░░░░░░░░░░░░░░░░░ |
| SGLT2 Inhibitors | 7,410 | █░░░░░░░░░░░░░░░░░░░ |
| CGM Technology | 6,729 | █░░░░░░░░░░░░░░░░░░░ |
| GWAS / Polygenic | 5,335 | █░░░░░░░░░░░░░░░░░░░ |
| Proteomics | 4,823 | █░░░░░░░░░░░░░░░░░░░ |
| Autoimmunity T1D | 4,574 | █░░░░░░░░░░░░░░░░░░░ |
| Remission T2D | 4,289 | █░░░░░░░░░░░░░░░░░░░ |
| Neuropathy | 3,160 | ░░░░░░░░░░░░░░░░░░░░ |
| Gene Therapy | 2,296 | ░░░░░░░░░░░░░░░░░░░░ |
| Health Equity | 1,990 | ░░░░░░░░░░░░░░░░░░░░ |
| Closed Loop / AP | 1,906 | ░░░░░░░░░░░░░░░░░░░░ |
| Multi-Omics | 1,694 | ░░░░░░░░░░░░░░░░░░░░ |
| Beta Cell Regen | 1,463 | ░░░░░░░░░░░░░░░░░░░░ |
| Treg / CAR-T | 953 | ░░░░░░░░░░░░░░░░░░░░ |
| Glucokinase | 854 | ░░░░░░░░░░░░░░░░░░░░ |
| Personalized Nutr | 661 | ░░░░░░░░░░░░░░░░░░░░ |
| Drug Repurposing | 609 | ░░░░░░░░░░░░░░░░░░░░ |
| LADA | 582 | ░░░░░░░░░░░░░░░░░░░░ |
| Islet Transplant | 248 | ░░░░░░░░░░░░░░░░░░░░ |

---

## How to Use This Analysis

1. **Meaningful gaps** are starting points for literature synthesis. For each, search PubMed with combined terms to verify the gap is real (not a terminology artifact).
2. **Methodologically distinct** pairs can be deprioritized unless a specific bridging mechanism is identified.
3. **Unclassified gaps** need expert review before action. Submit these to domain researchers for classification.
4. All gap scores should be validated against systematic review databases (Cochrane, PROSPERO) to confirm no existing reviews cover the intersection.

---

## Validation Status

| Aspect | Level | Notes |
|--------|-------|-------|
| Data source | PubMed E-utilities | Covers MEDLINE-indexed literature; misses preprints, grey literature |
| Gap scoring method | Published formula | Geometric mean normalization is standard in bibliometric analysis |
| Gap classifications | BRONZE | Single analyst classification; requires expert validation |
| Individual domain counts | Verifiable | Can be independently reproduced by querying PubMed directly |
| Temporal scope | 2020+ | Recent literature only; historical gaps may differ |

---

*Generated by Diabetes Research Hub — Literature Gap Analysis (Improved)*
*Methodology: Research Doctrine v1.0 — Triple-source validation pending for gap classifications*
